Search Bar & Filters
Found 28 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are evaluating BNT324 compared to the standard chemotherapy docetaxel combined with prednisone or prednisolone in men with metastatic castration-resistant prostate cancer mCRPC who have been previously treated with androgen receptor pathway inhibitors but have not received taxane-based chemotherapy for mCRPC. This phase III trial aims to determine if BNT324 can help participants live longer without their cancer worsening and improve overall survival. Participants are randomly assigned to one of two groups receiving BNT324 through intravenous infusion or receiving docetaxel intravenously along with oral prednisone or prednisolone. Treatment is given in 21-day cycles and continues until the cancer progresses, side effects become unacceptable, the participant decides to stop, or the study concludes. The study includes a screening period lasting up to 28 days, followed by treatment and an after-treatment period that includes a 30-day safety follow-up and a long-term survival follow-up. Participants will undergo assessments including scans reviewed centrally to monitor cancer progression, laboratory tests such as PSA levels, and evaluation of side effects. Researchers will track outcomes like radiographic progression-free survival and overall survival for up to approximately 58 months. Safety is closely monitored by an independent committee, and participants continue regular follow-up visits during and after treatment to assess response and manage any adverse events.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating alisertib monotherapy in patients with extensive stage small cell lung cancer SCLC who have experienced disease progression after treatment with one platinum-based chemotherapy and an anti-PD-L1PD-1 immunotherapy agent. This Phase 2 study aims to identify biomarker-defined subgroups that may benefit most from alisertib and to assess its effectiveness, safety, and how the drug behaves in the body. Participants will receive oral alisertib tablets in doses of 50 mg, 60 mg, or 70 mg taken twice daily on days 1 through 7 of each 21-day treatment cycle. The study includes only one treatment group receiving alisertib, with dose adjustments based on amendments. Treatment cycles will continue as defined by the study protocol. Throughout the study, participants will be monitored for tumor response including objective response rate, duration of response, disease control rate, progression-free survival, and overall survival, all within biomarker-defined subgroups and the enrolled population. Adverse events will be tracked from the first dose through 28 days after the last dose. The study duration for measuring outcomes is up to 36 months, with assessments conducted regularly during this period.
Actively Recruiting
Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.
Actively Recruiting
Researchers are evaluating the efficacy and safety of azenosertib ZN-c3, an oral selective WEE1 inhibitor, in women with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. This Phase 2 study focuses on patients whose tumors express Cyclin E1 protein, identified through a specialized assay. The study includes multiple parts, with Part 2 specifically enrolling Cyclin E1 positive patients to better understand the drugs impact in this subgroup. Participants receive azenosertib orally, following an intermittent dosing schedule of 400 mg once daily for 5 days, then 2 days off. Different dosing arms exist, including a 300 mg dose, all administered under careful monitoring. The study is randomized and open-label, with several parts completed and Part 2c actively enrolling. The treatment period and follow-up extend for up to approximately 12 months to assess various outcomes. During the study, participants undergo tumor testing, disease evaluation by standard imaging criteria RECIST v1.1, and monitoring of blood markers such as CA-125. Researchers track response rates, duration of response, progression-free survival, clinical benefit, and adverse events. Regular assessments ensure safety and treatment adherence. The total participation duration encompasses treatment and follow-up phases, with outcomes measured up to about one year after the last participant enrolls.
Actively Recruiting
Researchers are evaluating the combination of bleximenib with venetoclax VEN and azacitidine AZA compared to placebo with VEN and AZA alone for treating adults newly diagnosed with Acute Myeloid Leukemia AML who have specific gene mutations in NPM1 or KMT2A. This phase 3 randomized, double-blind study is designed for participants ineligible for intensive chemotherapy, aiming to understand how these treatments work in this population. Participants will receive treatment in 28-day cycles until disease progression or unacceptable side effects occur. One group will take oral bleximenib alongside oral venetoclax and intravenous or subcutaneous azacitidine, while the other group receives a placebo plus venetoclax and azacitidine. Treatment continues with regular cycles, and the study monitors effects over time. Throughout the study, participants will be assessed for response, including complete remission rates and overall survival, for up to more than four years. Researchers will also track event-free survival, duration and timing of remission, transfusion independence, adverse events, and blood levels of bleximenib. Safety and laboratory tests will be conducted regularly to monitor participant health and treatment effects.
Actively Recruiting
Researchers are studying the use of zilovertamab vedotin ZV combined with standard treatments for participants aged 18 and older who have relapsed or refractory diffuse large B-cell lymphoma rrDLBCL. This Phase 23, randomized, open-label study aims to evaluate the safety and effectiveness of ZV with treatments like rituximab, gemcitabine, and oxaliplatin R-GemOx, or bendamustine and rituximab BR. The study has two parts Dose Confirmation and Efficacy Expansion, focusing on progression-free survival and other outcomes. Participants will receive intravenous infusions of ZV at doses ranging from 1.5 mgkg to 2.5 mgkg along with R-GemOx or BR depending on their assigned group. Treatments are given on Day 1 of repeated 21-day cycles, continuing for up to six cycles or until disease progression or discontinuation. Some participants will receive standard R-GemOx or BR treatments without ZV. Prophylactic granulocyte colony-stimulating factor G-CSF is also given at each cycle of ZV as per guidelines. During the study, participants undergo assessments including monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations over several months. Researchers will measure overall survival, progression-free survival, objective response rate, and duration of response. Participants will be closely followed for up to approximately 68 months to track safety and effectiveness outcomes throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety of telisotuzumab vedotin in adults with previously treated non-squamous non-small cell lung cancer NSCLC that overexpresses the c-Met protein. This phase 2, open-label study aims to assess treatment-emergent adverse events, changes in disease activity, and how the drug behaves in the body. Approximately 150 participants will be enrolled worldwide and randomly assigned to one of three telisotuzumab vedotin dose groups. Participants will receive intravenous infusions of telisotuzumab vedotin at different doses as a monotherapy, administered over a three-year study period. The study compares three dosing regimens given by IV infusion, with participants assigned to one of three groups in a 111 ratio. Each participant will be treated and followed for up to three years to monitor safety and response. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, and monitoring of side effects. Questionnaires will be completed to report symptoms and quality of life. Researchers will track adverse events, including lung disease, neuropathy, and eye disorders, as well as treatment response and survival outcomes. The study includes ongoing safety monitoring and evaluation of drug levels in the blood throughout the treatment period.
1-10 of 28
1